China Universal Asset Management Co. Ltd. Acquires 5,926 Shares of Replimune Group, Inc. (NASDAQ:REPL)

China Universal Asset Management Co. Ltd. lifted its stake in Replimune Group, Inc. (NASDAQ:REPL) by 82.1% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 13,140 shares of the company’s stock after acquiring an additional 5,926 shares during the quarter. China Universal Asset Management Co. Ltd.’s holdings in Replimune Group were worth $144,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in REPL. Diversified Trust Co purchased a new position in shares of Replimune Group in the first quarter worth approximately $94,000. SG Americas Securities LLC bought a new stake in Replimune Group in the first quarter worth $147,000. Russell Investments Group Ltd. bought a new stake in shares of Replimune Group in the 1st quarter worth about $140,000. Entropy Technologies LP boosted its stake in shares of Replimune Group by 18.3% during the 1st quarter. Entropy Technologies LP now owns 59,326 shares of the company’s stock worth $485,000 after purchasing an additional 9,180 shares during the period. Finally, Vanguard Group Inc. grew its holdings in Replimune Group by 1.2% during the 1st quarter. Vanguard Group Inc. now owns 2,770,328 shares of the company’s stock valued at $22,634,000 after purchasing an additional 32,555 shares during the last quarter. Institutional investors own 92.53% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently weighed in on REPL shares. HC Wainwright reiterated a “buy” rating and set a $17.00 target price on shares of Replimune Group in a research report on Monday, September 16th. Roth Mkm started coverage on shares of Replimune Group in a report on Tuesday, August 27th. They issued a “buy” rating and a $17.00 target price for the company. Roth Capital upgraded Replimune Group to a “strong-buy” rating in a research note on Tuesday, August 27th. Finally, JPMorgan Chase & Co. upped their price objective on shares of Replimune Group from $14.00 to $17.00 and gave the company an “overweight” rating in a report on Tuesday, September 24th. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $16.80.

Insider Buying and Selling

In related news, CFO Emily Luisa Hill sold 8,938 shares of Replimune Group stock in a transaction on Friday, August 16th. The shares were sold at an average price of $10.18, for a total value of $90,988.84. Following the transaction, the chief financial officer now directly owns 101,057 shares in the company, valued at $1,028,760.26. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 20.60% of the company’s stock.

Replimune Group Trading Down 2.9 %

Shares of NASDAQ:REPL opened at $11.76 on Friday. The company has a market cap of $722.24 million, a PE ratio of -3.74 and a beta of 1.21. The company’s 50 day moving average is $11.07 and its two-hundred day moving average is $9.12. Replimune Group, Inc. has a 52 week low of $4.92 and a 52 week high of $15.02. The company has a current ratio of 13.46, a quick ratio of 13.46 and a debt-to-equity ratio of 0.16.

Replimune Group (NASDAQ:REPL) last posted its earnings results on Thursday, August 8th. The company reported ($0.78) EPS for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.10. Equities analysts predict that Replimune Group, Inc. will post -3.05 earnings per share for the current fiscal year.

Replimune Group Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.